Celyad SA Net Profit Margin 2014-2024 | CYAD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Celyad SA net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Celyad SA net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$146.3B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$114.2B
Vertex Pharmaceuticals (VRTX)	$108.7B
CSL (CSLLY)	$83.4B
Regeneron Pharmaceuticals (REGN)	$74.9B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$26.8B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$20.5B
Biogen (BIIB)	$20.5B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.8B
Genmab (GNMSF)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.4B
Moderna (MRNA)	$13.1B
Insmed (INSM)	$13B
Bio-Techne Corp (TECH)	$12B
BioMarin Pharmaceutical (BMRN)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
Vaxcyte (PCVX)	$10.6B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exact Sciences (EXAS)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$9B
Roivant Sciences (ROIV)	$8.1B